Publications

44 items matching your search terms.

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Alves, C. L.; Ehmsen, S.; Terp, M. G.; Portman, N.; Tuttolomondo, M.; Gammelgaard, O. L.; Hundebol, M. F.; Kaminska, K.; Johansen, L. E.; Bak, M.; Honeth, G.; Bosch, A.; Lim, E.; Ditzel, H. J.

Nature Communications 12 (1) :5112, 2021 10.1038/s41467-021-25422-9

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

Aziz, D.; Portman, N.; Fernandez, K. J.; Lee, C.; Alexandrou, S.; Llop-Guevara, A.; Phan, Z.; Yong, A.; Wilkinson, A.; Sergio, C. M.; Ferraro, D.; Etemadmoghadam, D.; Bowtell, D. D.; kConFab, Investigators; Serra, V.; Waring, P.; Lim, E.; Caldon, C. E.

NPJ Breast Cancer 7 (1) :111, 2021 10.1038/s41523-021-00312-x

Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

Chew, N. J.; Lim Kam Sian, T. C. C.; Nguyen, E. V.; Shin, S. Y.; Yang, J.; Hui, M. N.; Deng, N.; McLean, C. A.; Welm, A. L.; Lim, E.; Gregory, P.; Nottle, T.; Lang, T.; Vereker, M.; Richardson, G.; Kerr, G.; Micati, D.; Jarde, T.; Abud, H. E.; Lee, R. S.; Swarbrick, A.; Daly, R. J.

BREAST CANCER RESEARCH 23 (1) :82, 2021 10.1186/s13058-021-01461-4

Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review

Ardolino, L.; Lau, B.; Wilson, I.; Chen, J.; Borella, L.; Stone, E.; Lim, E.

Frontiers in Oncology 11 :701424, 2021 10.3389/fonc.2021.701424

Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis

Wu, S. Z.; Roden, D. L.; Al-Eryani, G.; Bartonicek, N.; Harvey, K.; Cazet, A. S.; Chan, C. L.; Junankar, S.; Hui, M. N.; Millar, E. A.; Beretov, J.; Horvath, L.; Joshua, A. M.; Stricker, P.; Wilmott, J. S.; Quek, C.; Long, G. V.; Scolyer, R. A.; Yeung, B. Z.; Segara, D.; Mak, C.; Warrier, S.; Powell, J. E.; O'Toole, S.; Lim, E.; Swarbrick, A.

Genome Medicine 13 (1) :81, 2021 10.1186/s13073-021-00885-z

Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer

Freelander, A.; Brown, L. J.; Parker, A.; Segara, D.; Portman, N.; Lau, B.; Lim, E.

Genes 12 (2) 2021 10.3390/genes12020285

Estrogen receptor positive breast cancer patient derived xenograft models in translational research.

Chia, K.; Freelander, A.; Kumar, S.; Parker, A.; Segara, D.; Portman, N.; Lim, E.

Current Opinion in Endocrine and Metabolic Research 15 :31-36, 2020

Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer

de Boer, R.; Hui, R.; Lim, E.; Yeo, B.; Zdenkowski, N.

Asia-Pacific Journal of Clinical Oncology 16 Suppl 5 :3-14, 2020 10.1111/ajco.13461

Stromal cell diversity associated with immune evasion in human triple-negative breast cancer

Wu, S. Z.; Roden, D. L.; Wang, C.; Holliday, H.; Harvey, K.; Cazet, A. S.; Murphy, K. J.; Pereira, B.; Al-Eryani, G.; Bartonicek, N.; Hou, R.; Torpy, J. R.; Junankar, S.; Chan, C. L.; Lam, C. E.; Hui, M. N.; Gluch, L.; Beith, J.; Parker, A.; Robbins, E.; Segara, D.; Mak, C.; Cooper, C.; Warrier, S.; Forrest, A.; Powell, J.; O'Toole, S.; Cox, T. R.; Timpson, P.; Lim, E.; Liu, X. S.; Swarbrick, A.

EMBO JOURNAL 1 (39) :e104063, 2020 10.15252/embj.2019104063

Testosterone therapy considerations in oestrogen, progesterone and androgen receptor-positive breast cancer in a transgender man

Light, M.; McFarlane, T.; Ives, A.; Shah, B.; Lim, E.; Grossmann, M.; Zajac, J. D.; Cheung, A. S.

CLINICAL ENDOCRINOLOGY 93 (3) :355-357, 2020 10.1111/cen.14263

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

Portman, N.; Milioli, H. H.; Alexandrou, S.; Coulson, R.; Yong, A.; Fernandez, K. J.; Chia, K. M.; Halilovic, E.; Segara, D.; Parker, A.; Haupt, S.; Haupt, Y.; Tilley, W. D.; Swarbrick, A.; Caldon, C. E.; Lim, E.

BREAST CANCER RESEARCH 22 (1) :87, 2020 10.1186/s13058-020-01318-2

Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer

Baker, L. A.; Holliday, H.; Roden, D.; Krisp, C.; Wu, S. Z.; Junankar, S.; Serandour, A. A.; Mohammed, H.; Nair, R.; Sankaranarayanan, G.; Law, A. M. K.; McFarland, A.; Simpson, P. T.; Lakhani, S.; Dodson, E.; Selinger, C.; Anderson, L.; Samimi, G.; Hacker, N. F.; Lim, E.; Ormandy, C. J.; Naylor, M. J.; Simpson, K.; Nikolic, I.; O'Toole, S.; Kaplan, W.; Cowley, M. J.; Carroll, J. S.; Molloy, M.; Swarbrick, A.

BREAST CANCER RES 22 (1) :63, 2020 10.1186/s13058-020-01306-6

Targeting CDK2 in cancer: challenges and opportunities for therapy

Tadesse, S.; Anshabo, A. T.; Portman, N.; Lim, E.; Tilley, W.; Caldon, C. E.; Wang, S.

DRUG DISCOVERY TODAY 25 (2) :406-413, 2020 10.1016/j.drudis.2019.12.001

Window of opportunity treatment in breast cancer

Chen, J.; Easwaralingam, N.; Warrier, S.; Ong, A.; Carson, E. K.; Mak, C.; Snook, K.; Middleton, K.; Parker, A.; Palmieri, C.; Spillane, A.; Mann, G. B.; Lim, E.; Segara, D.

ANZ JOURNAL OF SURGERY 90 (1-2) :34-40, 2020 10.1111/ans.15487

Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary

Grossmann, M.; Ramchand, S. K.; Milat, F.; Vincent, A.; Lim, E.; Kotowicz, M. A.; Hicks, J.; Teede, H. J.

MEDICAL JOURNAL OF AUSTRALIA 211 (5) :224-229, 2019 10.5694/mja2.50280

Estrogen receptor signaling is reprogrammed during breast tumorigenesis

Chi, D.; Singhal, H.; Li, L.; Xiao, T.; Liu, W.; Pun, M.; Jeselsohn, R.; He, H.; Lim, E.; Vadhi, R.; Rao, P.; Long, H.; Garber, J.; Brown, M.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 116 (23) :11437-11443, 2019 10.1073/pnas.1819155116